Key result
Intravenous acetylcysteine during hemodialysis significantly improved arterial vascular reactivity, decreasing the reflective index to 30.2 ± 10.3 during reactive hyperemia (p < 0.01).
Why the study?
Does intravenous acetylcysteine improve arterial vascular reactivity in patients with stage 5 chronic kidney disease undergoing hemodialysis?
Population
n=24 patients with stage 5 chronic kidney disease undergoing hemodialysis
Comparison
Acetylcysteine continuously administered… vs Placebo during hemodialysis in a cross-over design
Design
RCT, randomized cross-over, placebo-controlled
Follow-up
immediately after one hemodialysis session
Authors
Loading...
Acetylcysteine during hemodialysis improves arterial reactivity; extends antioxidant effects to randomized evidence in stage 5 CKD.
RCT (n=24)
cross-over
Does intravenous acetylcysteine improve arterial vascular reactivity in patients with stage 5 chronic kidney disease undergoing hemodialysis?
Absolute Event Rate: 30.2% vs 33.8%
p-value: p=<0.01
Intravenous acetylcysteine administered during hemodialysis significantly improves arterial vascular reactivity in patients with stage 5 chronic kidney disease.
Wittstock et al. (2009) conducted an RCT in stage 5 chronic kidney disease (n=24). Acetylcysteine vs. Placebo was evaluated on reflective index during reactive hyperemia (p=<0.01). Intravenous acetylcysteine during hemodialysis significantly improved arterial vascular reactivity, decreasing the reflective index to 30.2 ± 10.3 during reactive hyperemia (p < 0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: